3
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
1
Phase 1
1
Status
Terminated
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Dermatologic
4
Genitourinary
3
Thoracic
2
Sarcoma
2
Head & Neck
2
Gastrointestinal
2
Breast
2
Other solid neoplasm
1
Other hematologic neoplasm
1
Lymphoid
1
CNS
1
Conditions
Sarcoma, Ewing
1
Rhabdomyosarcoma
1
Recurrence
1
Neuroblastoma
1
Neoplasms
1
Melanoma
1
Medulloblastoma
1
Lymphoma, Non-Hodgkin
1
Lymphoma
1
Leukemia, B-Cell
1
Leukemia
1
Glioma
1
Ependymoma
1
Interventions
Rituximab
169
Cyclophosphamide
158
fludarabine
76
Lenalidomide
73
Vincristine
70
fludarabine phosphate
63
Etoposide
59
Doxorubicin
56
Prednisone
54
venetoclax
49
Cytarabine
48
Dexamethasone
43
Filgrastim
39
Peripheral Blood Stem Cell Transplantation
38
Methotrexate
38
Bendamustine Hydrochloride
38
ibrutinib
37
obinutuzumab
36
Gemcitabine
31
pembrolizumab
27
Melphalan
27
Bortezomib
27
Alemtuzumab
25
Radiotherapy
23
Nivolumab
21
Carboplatin
21
Tacrolimus
20
Granulocyte Colony-Stimulating Factor
20
Busulfan
20
Whole-Body Irradiation
19
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 1/2
×
bempegaldesleukin
×
Lymphoid
×
Clear all
NCT04730349
2023-03-24
PIVOT IO 020
Bristol-Myers Squibb
Phase 1/2
Terminated
15 enrolled
14 charts